At this year's annual meeting of the American Society of Clinical Oncology (ASCO 2015), held May 29 through June 2 in Chicago, specialists discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were in attendance to report highlights of the conference. Here, Editor-in-Chief William J. Gradishar, MD, reviews key presentations on new breast cancer treatments. All meeting abstracts can be viewed in the ASCO meeting library).
Palbociclib for Hormone-Receptor–Positive Advanced Breast Cancer
Palbociclib is a recently FDA-approved, oral, small-molecule inhibitor of the cyclin-dependent 4/6 kinases that block the transition of the cell cycle from the G1 phase to the S phase and also inhibits phosph…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)